GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PHAXIAM Therapeutics SA (XPAR:PHXM) » Definitions » General and Admin. Expense

PHAXIAM Therapeutics (XPAR:PHXM) General and Admin. Expense : €4.30 Mil (TTM As of Sep. 2023)


View and export this data going back to 2013. Start your Free Trial

What is PHAXIAM Therapeutics General and Admin. Expense?

General and Admin. Expense is the aggregate total of general managing and administering expenses for the company. PHAXIAM Therapeutics's General and Admin. Expense for the three months ended in Sep. 2023 was €2.96 Mil. Its General and Admin. Expense for the trailing twelve months (TTM) ended in Sep. 2023 was €4.30 Mil.


PHAXIAM Therapeutics General and Admin. Expense Historical Data

The historical data trend for PHAXIAM Therapeutics's General and Admin. Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PHAXIAM Therapeutics General and Admin. Expense Chart

PHAXIAM Therapeutics Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
General and Admin. Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 14.07 16.41 13.21 13.97 12.21

PHAXIAM Therapeutics Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Jun23 Sep23
General and Admin. Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.13 3.80 1.34 - 2.96

PHAXIAM Therapeutics General and Admin. Expense Calculation

General and Admin. Expense is the aggregate total of general managing and administering expenses for the company.

General and Admin. Expense for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €4.30 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


PHAXIAM Therapeutics General and Admin. Expense Related Terms

Thank you for viewing the detailed overview of PHAXIAM Therapeutics's General and Admin. Expense provided by GuruFocus.com. Please click on the following links to see related term pages.


PHAXIAM Therapeutics (XPAR:PHXM) Business Description

Traded in Other Exchanges
Address
60 Avenue Rockefeller, Lyon, FRA, 69008
Erytech Pharma SA is a clinical-stage biopharmaceutical company developing innovative therapies for severe forms of cancer and orphan diseases. Its ERYCAPS platform, uses a novel technology to encapsulate therapeutic drug substances inside erythrocytes, or red blood cells, or RBC. It is developing a pipeline of product candidates for patients with high unmet medical needs. Its lead product candidate eryaspase, also referred as GRASPA, targets the metabolism of cancer cells by depriving the cells of asparagine, an amino acid necessary for their survival and critical in maintaining the cells' rapid growth rate. The company is developing eryaspase for the treatment of severe tumors, including pancreatic cancer, acute lymphoblastic leukemia, or ALL, and triple negative breast cancer, or TNBC.

PHAXIAM Therapeutics (XPAR:PHXM) Headlines

From GuruFocus

ERYTECH Announces Poster Presentations at ASCO 2020 Annual Meeting

By Marketwired Marketwired 06-01-2020

ERYTECH Appoints Stewart Craig as Chief Technical Officer

By Marketwired Marketwired 10-27-2020